Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, today announced that it will release financial results for the third quarter of 2019 after the close of trading on Tuesday, November 12, 2019. Valeritas’ management team will host a corresponding conference call beginning at 4:30 p.m. ET. Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies.
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
Boston Scientific (BSX) is hopeful about robust data outcome on DAPT study as the therapy duration might prove to be a superior treatment option.
Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced positive data from its preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion was presented as a late-breaking poster presentation on Sunday, December 8 at the American Epilepsy Society 2019 Annual Meeting in Baltimore, Maryland. The Company believes this study represents the first report of CBD isolate delivered via subcutaneous infusion in any preclinical model. In the poster presentation titled “Therapeutic Plasma Levels of Cannabinoid (CBD) in Dogs Delivered Via h-Patch™ Subcutaneous Infusion,” the Company showcased for the first time data from both 40mg and 76mg of CBD isolate delivered over 24 hours with the h-Patch™ technology.
Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses their proprietary h-Patch™ technology, announced today positive topline results from a preclinical pharmacokinetic (PK) study. The study evaluated subcutaneous infusion of a GLP-1 analogue via its proprietary h-Patch™ wearable drug delivery device. Valeritas’ h-Patch™ is a drug delivery technology that can facilitate the simple and effective subcutaneous delivery of injectable medicines to patients across a broad range of therapeutic areas.
Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, today announced revised revenue guidance and preliminary financial results for the fourth quarter and year ended December 31, 2019 as a result of a manufacturing yield issue that has caused a temporary disruption in supply. The issue has caused a delay in available product and the Company will be unable to ship product until the issue is resolved and the supply chain is replenished. The Company is working toward resuming shipment as soon as possible and will provide additional information as it becomes available.
NuVasive (NUVA) aims to speed up the adoption of less invasive spine surgery through robotics.
Q3 2019 Valeritas Holdings Inc Earnings Call
Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced positive data from its preclinical pharmacokinetic (PK) study of apomorphine (APO) subcutaneous infusion was presented today at Global Experts Meeting on Frontiers in Alzheimer’s Disease & Dementia (Dementia 2019) in Rome, Italy. In the poster presentation titled “Preclinical Pilot Study Result of 24-Hour Apomorphine Subcutaneous Infusion Delivered via the h-Patch™ Wearable Device,” the data demonstrated rapid absorption and distribution of 400ul of a 25mg/ml APO solution with the h-Patch™ technology. APO was detected in plasma within two hours of the start of infusion, and still detectable 24 hours after completion of h-Patch™ infusion, or 48 hours in total.
Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, today announced additional data from the VERDICT study presented at the 19th Annual Diabetes Technology Meeting held in Bethesda, Maryland. This data demonstrated positive clinical outcomes for patients with type 2 diabetes who switched insulin therapy to V-Go from a basal-only, basal-bolus, or premix insulin regimen. This real-world retrospective analysis was performed using electronic medical records to identify 122 patients with uncontrolled type 2 diabetes (A1c > 7.0%) who switched to V-Go from traditional insulin injection therapy regimens.
BRIDGEWATER, N.J., Nov. 12, 2019 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple,.
Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today a poster presentation at the 24th World Congress of Neurology held in Dubai, UAE, on October 27-31, 2019. On August 5th, Valeritas announced positive results from a preclinical pharmacokinetic (PK) study of continuous subcutaneous infusion of apomorphine (Apo) delivered via its proprietary h-Patch™ wearable drug delivery device.
Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today the restructuring of a substantial portion of its outstanding long-term debt, reducing the total debt balance by an aggregate of $25.0 million. Under the terms of the debt restructuring, $25.0 million of Valeritas senior secured long-term debt held by CR Group L.P. (CRG) affiliated funds and another creditor was exchanged for newly created Valeritas Series B Convertible Preferred Stock, the terms of which are disclosed in a Form 8-K to be filed with the SEC. The debt exchange reduces the outstanding balance of senior secured debt to approximately $17.0 million.
Haemonetics (HAE) is gaining traction from a steady progress in Plasma franchise.
Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today it will be hosting an educational symposium and participating at the Metabolic & Endocrine Disease Summit (MEDS) in Orlando, Florida. On October 4, Valeritas will be hosting an educational breakfast where attendees will be given an opportunity to learn and broaden their knowledge and understanding of V-Go and how its proper use can lead to lower insulin dose requirements and lower diabetes-related medication cost while lowering average blood sugar levels, as measured by A1c. “We are very excited to participate in the 2019 MED East Summit, as it is designed to enhance the knowledge base of those healthcare professionals who diagnose, manage, and treat metabolic and endocrine diseases,” said John Timberlake, President and Chief Executive Officer of Valeritas.
Valeritas Holdings, Inc. (NASDAQ: VLRX) ("Valeritas" or the "Company"), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, today announced an agreement to sell substantially all of the business to Zealand Pharma A/S (NASDAQ: ZEAL) ("Zealand"), a Denmark-based biotechnology company. The transaction contemplates the retention of nearly the entirety of the Valeritas workforce.
Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced positive data from its preclinical pharmacokinetic (PK) study of apomorphine (Apo) subcutaneous infusion was presented today at the 24th World Congress of Neurology held in Dubai, UAE. In the poster presentation titled “Delivery of Apomorphine via Subcutaneous Infusion with the h-Patch™ Wearable Device,” the data demonstrated that 400ul of a 25mg/ml Apo solution delivered with the h-Patch™ technology was rapidly absorbed and was detected in plasma within two hours of the start of infusion. Additionally, Apo was still detectable in plasma 24 hours after completion of h-Patch™ infusion, or 48 hours in total.
Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today a poster presentation at the American Epilepsy Society's Annual Meeting held in Baltimore, Maryland, on December 6-10, 2019. On July 30th, Valeritas announced positive results from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion with two dosing regimens delivered via its proprietary h-Patch™ wearable drug delivery device. The company believes this study represents the first report of CBD delivered via subcutaneous infusion in any preclinical model.
Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today that Dr. Jessica Barnes, consultant to the company, will be a panelist at CBD Expo EAST 2019 being held November 15-16, 2019, at the Hilton Orlando in Orlando, Florida. The past year’s breakthroughs in CBD research include medication interactions, epilepsy, neuroscience, dermatological applications, mental health disorders, addiction/relapse, and biochemistry. On July 30th, Valeritas announced positive results from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion with two dosing regimens delivered via its proprietary h-Patch™ wearable drug delivery device.
Within Diabetes group, Medtronic (MDT) is seeing a strong adoption of the Guardian Connect Smart CGM system.